Prostate Cancer - Results from #40

An editorial on a comparison of care quality metrics between Black and White men with advanced prostate cancer in the IRONMAN registry. May 31, 2023

Improved Analysis of Prostate Cancer: VIM3, ATG7 and P53 Form a Complex and Activate miRNA 371a-3p. May 31, 2023

Regional disparities of prostate cancer mortality in Ecuador: an examination of trends and correlates from 2004 to 2019. May 31, 2023

Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data. May 31, 2023

Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. May 31, 2023

Evaluation of initial prostate cancer biopsies utilizing 3D open-top light-sheet microscopy for detection of early disease. May 31, 2023

Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. May 31, 2023

Nuclear morphology predicts cell survival to cisplatin chemotherapy. May 31, 2023

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. May 31, 2023

Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence. May 31, 2023

The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. May 31, 2023

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer May 30, 2023

Imaging quality of an artificial intelligence denoising algorithm: validation in 68Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer. May 30, 2023

A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. May 30, 2023

Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index. May 30, 2023

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). May 30, 2023

Trends in prostate cancer incidence among Black men in the Caribbean and the United States. May 30, 2023

Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. May 30, 2023

Experience with the US health care system for Black and White patients with advanced prostate cancer. May 30, 2023

Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report. May 29, 2023

Page 3 of 1306